Dongin (Donoven) Kim, Ph.D.

---

Publications & Presentations

46. Dasari M, Lee S, Sy J, Kim D, Lee S, Brown M, Davis M, Murthy N. Hoechst-IR: an imaging agent that detects necrotic tissue in vivo by binding extracellular DNA. Organic letters. 2010; 12 : 3300-3

47. Kim D, Gao Z G, Lee E S, Bae Y H. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Molecular pharmaceutics. 2009; 6 : 1353-62

48. Oh K T, Kim D, You H H, Ahn Y S, Lee E S. pH-sensitive properties of surface charge-switched multifunctional polymeric micelle. International journal of pharmaceutics. 2009; 376 : 134-40

49. Kim D, Lee E S, Oh K T, Gao Z G, Bae Y H. Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small (Weinheim an der Bergstrasse, Germany). 2008; 4 : 2043-50

50. Gao Z, Lee D, Kim D, Bae Y H. Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice. Journal of Drug Targeting. 2008; 13 : 391-397

Grants

1. Drug-Targeting ORP4 as a Precision Ovarian Cancer Target. DOD. Start Date: 2025. End Date: 2029.

2. Extracellular Vesicle-Based Intraocular Therapy Combined with Active Targeting of Ocular Neovascularization. NEI. Start Date: 2024. End Date: 2029.

3. MiPEP133, a New Tumor Suppressor for Ovarian Cancer. American Cancer Society. Start Date: 2024. End Date: 2027.

4. Preclinical assessment of exosomal drug delivery system using innovative tumor mouse model. Misc Non-Federal. Start Date: 2024. End Date: 2026.

5. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.

Awards and Honors

no results

Education

1. Degree: Ph D. University of Utah. Date: 2009.


2. Degree: MS. University of Florida. Date: 2002.


3. Degree: BS. Ajou University. Date: 1999.

Administrative Assignments

no results